RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO...

Descripción completa

Detalles Bibliográficos
Autores principales: Oronsky, Bryan, Carter, Corey A., Caroen, Scott, Scribner, Curtis, Oronsky, Arnold, Reid, Tony R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Back Matter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790525/
https://www.ncbi.nlm.nih.gov/pubmed/33457091
http://dx.doi.org/10.1080/2162402X.2020.1746172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790525/
https://www.ncbi.nlm.nih.gov/pubmed/33457091
http://dx.doi.org/10.1080/2162402X.2020.1746172

Ejemplares similares